Want to see SXTP full AI Analyst Report?
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-32.43% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by heavy and persistent losses plus ongoing cash burn despite improving revenue and a currently debt-free balance sheet. Technicals add further pressure with a broad downtrend and negative momentum. Corporate updates provide some upside optionality via clinical/regulatory milestones, but near-term fundamentals and price trend remain the main constraints.
Positive Factors
Revenue Growth
Revenue growth indicates improving commercial traction for the company’s malaria products. Sustained top-line expansion could improve operating leverage over time if distribution broadens and customer demand continues to develop.
Negative Factors
Severe Unprofitability
Losses remain extremely large relative to revenue, showing that the current cost structure overwhelms gross profit. Without substantial revenue growth or expense reductions, the company may struggle to achieve sustainable operating leverage and profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth indicates improving commercial traction for the company’s malaria products. Sustained top-line expansion could improve operating leverage over time if distribution broadens and customer demand continues to develop.
Read all positive factors
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.97M
Dividend YieldN/A
Average Volume (3M)199.18K
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue Growth24.77%
EPS Growth86.32%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.05
Shares Outstanding3,516,988
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.70Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.3
Revenue Forecast (FY)$900.00K
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an ap...
How the Company Makes Money
The company makes money primarily by selling its tafenoquine-based malaria products. Key revenue streams include (1) product sales of Arakoda (tafenoquine) in the United States, generated through distribution to pharmacies/wholesalers and other ch...
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11M | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M |
| Gross Profit | 215.79K | 223.78K | 222.81K | -220.98K | -209.16K | 309.60K |
| EBITDA | -8.07M | -7.28M | -7.88M | -1.43M | -2.11M | -1.01M |
| Net Income | -8.11M | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
Balance Sheet | ||||||
| Total Assets | 4.28M | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02M | 2.75M | 3.39M | 2.14M | 264.87K | 115.40K |
| Total Debt | 151.18K | 152.78K | 155.89K | 172.67K | 22.42M | 18.80M |
| Total Liabilities | 1.75M | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Stockholders Equity | 2.61M | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
Cash Flow | ||||||
| Free Cash Flow | -8.95M | -7.07M | -5.83M | -4.66M | -1.07M | -684.50K |
| Operating Cash Flow | -8.77M | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K |
| Investing Cash Flow | -288.34K | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K |
| Financing Cash Flow | 8.11M | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
1.48
Price Trends
1.44
Negative
1.53
Negative
2.41
Negative
Market Momentum
-0.10
Negative
36.78
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.44, and below the 200-day MA of 2.41, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.97M | -0.19 | -200.17% | ― | 24.77% | 86.32% | |
| ― | $2.39M | -0.15 | -177.32% | ― | ― | 86.26% | |
42 Neutral | $17.41M | -0.04 | -1335.64% | ― | ― | 78.25% | |
33 Underperform | $2.81M | -0.08 | -105.46% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
SXTP
60 Degrees Pharmaceuticals, Inc.
1.13
-4.07
-78.27%
OGEN
Oragenics
0.54
-0.54
-50.00%
KALA
KALA BIO
0.84
-424.16
-99.80%
KTTA
Pasithea Therapeutics Corp
0.47
-0.24
-33.80%
SPRC
SciSparc Ltd.
6.63
-31.45
-82.60%
ONCO
Onconetix
0.67
-139.83
-99.53%
60 Degrees Pharmaceuticals, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions
Positive
Aug 6, 2026
On August 5, 2026, 60 Degrees Pharmaceuticals, Inc. held its virtual 2026 annual stockholders meeting, with about 41.6% of outstanding voting shares represented, and shareholders elected five directors to serve until the 2027 meeting while ratifyi...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
Neutral
Aug 4, 2026
On July 30, 2026, 60 Degrees Pharmaceuticals entered into definitive securities purchase agreements with institutional investors for a private placement of common stock or pre-funded warrants, along with Series A and short-term Series B warrants, ...
Business Operations and StrategyRegulatory Filings and Compliance
60 Degrees updates strategy for ARAKODA and profitability
Neutral
Jul 20, 2026
On July 20, 2026, 60 Degrees Pharmaceuticals updated its investor presentation for ongoing use with the investment community, outlining its strategy around ARAKODA and broader vector-borne disease programs. The materials highlighted the company...
Business Operations and StrategyRegulatory Filings and Compliance
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study
Positive
Jul 9, 2026
On July 7, 2026, 60 Degrees Pharmaceuticals finalized a statistical analysis plan for an interim review of its randomized, placebo-controlled trial of tafenoquine in hospitalized patients with severe babesiosis. The plan sets detailed rules for ti...
Business Operations and Strategy
60 Degrees details tafenoquine priority review voucher strategy
Positive
Jun 3, 2026
60 Degrees Pharmaceuticals disclosed that it plans to apply for a Commissioner’s National Priority Review Voucher if interim or final results from its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.